TABLE 3.
Ezetimibe pharmacokinetic parameters based on sex, biogeographical origin, clinical trial and co-administration of drugs.
| N | AUC72h/DW (h a ng a kg/mL a mg) | Cmax/DW (ng a kg/mL a mg) | tmax (h) | |
|---|---|---|---|---|
| Sex | ||||
| Men | 51 | 702.49 (263.96) | 33.24 (14.65) | 5.50 (1.25–6.50) |
| Women | 45 | 750.95 (305.26) | 37.07 (20.93) | 5.50 (1.50–6.00) |
| Biogeographical Origin | ||||
| European | 80 | 737.55 (289.10) | 35.84 (18.83) | 5.50 (1.50–6.00) |
| Latin-American | 13 | 639.96 (232.90) | 31.03 (12.67) | 6.00 (0.50–10.25) |
| Other b | 3 | 765.45 (370.58) | 31.01 (7.51) | 1.50 (1.50–2.50) a |
| Clinical Trial | ||||
| A | 33 | 737.17 (316.01) | 32.50 (17.13) | 6.00 (1.50–6.50) |
| B | 11 | 743.27 (320.04) | 31.62 (7.98) | 6.00 (1.50–6.50) |
| C | 30 | 666.81 (252.05) | 36.24 (17.44) | 2.50 (1.00–6.00) |
| D | 22 | 777.86 (258.77) | 38.91 (22.68) | 5.50 (1.69–6.13) |
| Co-administration of drugs | ||||
| Ezetimibe | 44 | 738.69 (313.28) | 32.28 (15.28) | 6.00 (1.50–6.50) |
| Ezetimibe/Simvastatin | 52 | 713.80 (258.39) | 37.37 (19.66) | 3.00 (1.25–6.00) |
Data are shown as mean (standard deviation) for normal distributions and median (Q25-Q75) for non-normal distributions. AUC: area under the curve. DW: dose/weight ratio. Cmax: maximum concentration. Tmax: time to Cmax.
a
It is not possible to generate quartiles, therefore, the range of the data is shown for this result.
b
Other: one volunteer self-reported as Near Eastern and two as East Asian.